Venous thromboembolism risk assessment

Venous thromboembolism (VTE) is a major cause of death in hospital patients, and there are considerable costs associated with non-fatal symptomatic VTE and related comorbidities. The first step in preventing death and disability is to identify those who are at risk so that preventative treatments can be used. The VTE risk assessment was formally a national Commissioning for Quality and Innovation (CQUIN) indicator and is a National Quality Requirement in the NHS Standard Contract for 2016/17. It sets a threshold rate that acute providers must undertake risk assessments for at least 95% of inpatients each month.

How has the rate of venous thromboembolism (VTE) risk assessment changed?

Since 2010/11 Q1, there has been an increase in the proportion of adult admissions being risk assessed for venous thromboembolism (VTE) across all providers of NHS-funded acute care. The 95% target was introduced in 2013/14 as part of the national VTE CQUIN goal, and the 95% threshold has been exceeded for all providers since 2013/14 Q1. In 2016/17 Q4, the proportion of adult inpatients who were risk assessed for VTE on admission to hospital was 95.5% for acute providers and 97.8% for independent sector providers.

Updated December 2017.

About this data

Adherence to national guidance around VTE risk assessment has the potential to save many lives each year.

The data presented here relates to the proportion of adult hospital admissions admitted during the analysis period who are risk assessed for VTE on admission to hospital according to the Department of Health/NICE National VTE Risk Assessment Tool.

All providers of NHS-funded acute hospital care (including foundation and non-foundation trusts and independent sector providers) are required to complete the data collection, which was mandated in June 2010.

Comments

As a recently-retired physician, I followed this directive as best I could in recent years.
Has there been any impact in outcomes from all this frenetic (& costly) activity - ie morbidity & mortality from VTE? I haven't seen any evidence to support this.

Kit Byatt (not verified)
(changed )

Add new comment